Prostate surface membrane antigen (PSMA)-PET imaging has significantly shaped the clinical management of prostate cancer, from localized to metastatic disease. It outperforms conventional imaging in both primary staging and detecting recurrence. PSMA-PET incorporation into the clinical workflow can alter treatment decisions, though the impact of observed stage migration on patient outcomes has yet to be well-characterized. There is growing interest in using PSMA-PET to predict treatment response across all stages of prostate cancer, and to select patients for PSMA radioligand therapy. Use of PSMA-PET will continue to expand for clinical applications as its role becomes better defined through prospective studies.
PET clinics. 2025 Feb 08 [Epub ahead of print]
Jarey H Wang, Xiaolei Shi, Phuoc T Tran, Philip Sutera
Department of Radiation Oncology, Johns Hopkins University School of Medicine, 401 N Broadway Street, Baltimore, MD 21287, USA., Department of Hematology/Oncology, University of Maryland Medical Center, 22 S. Greene Street, Baltimore, MD 21201, USA., Department of Radiation Oncology, University of Maryland Medical Center, 850 W. Baltimore Street, Baltimore, MD 21201, USA., Department of Radiation Oncology, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA. Electronic address: .